Key Points
- Palvella COO Kathleen Goin sold 4,302 shares at an average price of $152.24, generating $654,936.48. The Rule 10b5-1 transaction reduced her holdings by 66.64%, leaving her with 2,154 shares.
- PVLA opened at $150.56 and remains near its 52-week high of $161.38, with a $2.17 billion market capitalization. The company reported a quarterly EPS loss of $1.52, missing the $1.17 analyst consensus.
- Analysts maintain an overall “Buy” rating with a consensus price target of $209.14, while institutional investors own 40.11% of the company; Palvella is developing therapies for rare genetic and dermatologic diseases.
Palvella Therapeutics, Inc. (NASDAQ:PVLA - Get Free Report) COO Kathleen Goin sold 4,302 shares of the business's stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $152.24, for a total value of $654,936.48. Following the completion of the sale, the chief operating officer owned 2,154 shares of the company's stock, valued at $327,924.96. This trade represents a 66.64% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Kathleen Goin also recently made the following trade(s):
- On Wednesday, August 19th, Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock. The stock was sold at an average price of $152.21, for a total value of $654,807.42.
Palvella Therapeutics Price Performance
PVLA stock opened at $150.56 on Friday. Palvella Therapeutics, Inc. has a fifty-two week low of $56.22 and a fifty-two week high of $161.38. The stock has a market capitalization of $2.17 billion, a price-to-earnings ratio of -31.17 and a beta of -0.25. The business's fifty day moving average price is $149.44 and its two-hundred day moving average price is $132.90.
Palvella Therapeutics (NASDAQ:PVLA - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($1.52) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.35). Research analysts expect that Palvella Therapeutics, Inc. will post -6.36 EPS for the current year.
Analysts Set New Price Targets
A number of research firms have issued reports on PVLA. Truist Financial set a $207.00 price objective on shares of Palvella Therapeutics in a report on Wednesday, August 5th. HC Wainwright reiterated a "buy" rating and issued a $270.00 price target on shares of Palvella Therapeutics in a research report on Wednesday, July 22nd. Chardan Capital upgraded Palvella Therapeutics to a "strong-buy" rating in a research note on Tuesday, July 28th. Canaccord Genuity Group set a $232.00 price target on Palvella Therapeutics in a research report on Wednesday, August 5th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Palvella Therapeutics in a research note on Monday, June 29th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Palvella Therapeutics has an average rating of "Buy" and a consensus price target of $209.14.
Check Out Our Latest Analysis on Palvella Therapeutics
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in PVLA. Arizona State Retirement System lifted its holdings in shares of Palvella Therapeutics by 30.9% during the second quarter. Arizona State Retirement System now owns 2,765 shares of the company's stock worth $423,000 after purchasing an additional 652 shares during the period. Northwestern Mutual Wealth Management Co. acquired a new stake in Palvella Therapeutics during the 2nd quarter valued at approximately $35,000. Penn Capital Management Company LLC bought a new position in Palvella Therapeutics during the 2nd quarter worth approximately $841,000. Hsbc Holdings PLC bought a new position in Palvella Therapeutics during the 2nd quarter worth approximately $7,641,000. Finally, Wellington Management Group LLP lifted its position in shares of Palvella Therapeutics by 4.6% in the 2nd quarter. Wellington Management Group LLP now owns 35,594 shares of the company's stock worth $5,439,000 after purchasing an additional 1,554 shares during the period. Institutional investors own 40.11% of the company's stock.
Palvella Therapeutics Company Profile
(
Get Free Report)
Palvella Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for patients with rare genetic and dermatologic diseases. The company uses its proprietary QTORIN platform to formulate and deliver medicines locally to affected tissues, with the goal of improving treatment effectiveness while limiting systemic exposure.
Palvella's lead program is QTORIN 3.9% rapamycin, an investigational topical gel being developed for microcystic lymphatic malformations, rare lesions caused by abnormalities in the lymphatic system.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
